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Abstract
Epithelial–mesenchymal transition (EMT) is important for tumour cell invasion and metastasis and is a feature of
aggressive carcinomas. EMT is characterised by reduced E-cadherin and increased N-cadherin expression (EN-
switch), and increased expression of the EMT-regulating transcription factor Forkhead box protein C2 (FOXC2)
has been associated with progression and poor prognosis in various malignancies. FOXC2 was recently
highlighted as a novel therapy target in prostate cancer, but survival data on FOXC2 are lacking. This study eval-
uates the expression of FOXC2, E-cadherin and N-cadherin in different prostatic tissues focusing on EMT,
clinico-pathological phenotype, recurrence and patient survival. Tissue microarray sections from 338 radical pros-
tatectomies (1986–2007) with long and complete follow-up, 33 castration resistant prostate cancers, 33 non-
skeletal metastases, 13 skeletal metastases and 41 prostatic hyperplasias were stained immunohistochemically
for FOXC2, E-cadherin and N-cadherin. FOXC2 was strongly expressed in primary carcinomas, including castra-
tion resistant tumours and metastatic lesions as compared to benign prostatic hyperplasia. A hybrid epithelial–
mesenchymal phenotype, with co-expression of E-cadherin and N-cadherin, was found in the majority of skeletal
metastases and in a substantial proportion of castration resistant tumours. In localised carcinomas, the EN-switch
was associated with adverse clinico-pathological variables, such as extra-prostatic extension, high pathological
stage and lymph node infiltration. In univariate survival analyses of the clinically important, large subgroup of
199 patients with Gleason score 7, high FOXC2 expression and EN-switching were significantly associated with
shorter time to clinical recurrence, skeletal metastases and cancer specific death. In multivariate Cox’ survival
analysis, high FOXC2 and the EN-switch, together with Gleason grade group (GG3 versus GG2), were independent
predictors of time to these end-points. High FOXC2 gene expression (mRNA) was also related to patient out-
come, validating our immunohistochemical findings. FOXC2 and factors signifying EMT or its intermediate states
may prove important as biomarkers for aggressive disease and are potential novel therapy targets in prostate
cancer.
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Introduction
Prostate cancer is one of the leading causes of cancer-
related death among males. An increasing number of
men are diagnosed with this disease due to extensive
serum prostate-specific antigen (s-PSA) testing. The
heterogeneity of prostate carcinomas makes it impor-
tant to improve prognostication and stratification to
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avoid over-treatment of indolent cancers and identify
the aggressive ones requiring radical treatment, sys-
temic or targeted molecular therapy.
Forkhead box protein C2 (FOXC2) is an epithelial-
to-mesenchymal transition (EMT)-regulating transcrip-
tion factor of the forkhead/winged helix-family [1].
EMT is a conserved embryonic cellular trans-
differentiation programme, seen in development and
pathological conditions such as wound healing, fibro-
sis and in aggressive carcinomas [2,3]. In EMT, the
polarised epithelial tumour cells shift to a motile,
mesenchymal-like phenotype, thereby enabling the
tumour cells to become invasive and to metastasise
[3,4]. During EMT, tumour cells experience loss of
apical-basal polarity due to reduced E-cadherin (adhe-
rens junctions), gain of N-cadherin, and loss of tight
junctions and desmosomes. Tumour EMT is initiated
and controlled by multiple signalling pathways,
involving transforming growth factor β (TGFβ) [5,6],
and transcription factors Twist, Slug, Snai1, ZEB1 and
others [5]. However, there have been relatively few
studies on EMT-related markers and the progress and
prognosis of prostate cancer [7–10].
FOXC2 has been shown to induce EMT in coopera-
tion with other EMT regulating transcription factors
like Slug and Twist [1], and was newly brought to
attention by the identification of a small molecule
inhibiting this factor [11]. FOXC2 seems to act as a
mesenchymal inductor at a later stage during EMT,
and its expression has been associated with aggressive
human breast cancers [12]. In non-small-cell lung car-
cinoma, FOXC2 mediates the transcriptional repres-
sion of p120-catenin, which is a positive regulator of
E-cadherin [13]. In gastric cancer, FOXC2 was found
to positively regulate N-cadherin expression by
SENP3 [14]. Beyond its function as an EMT regulator,
FOXC2 promotes cell proliferation and is a mediator
of angiogenesis and lymphangiogenesis [15,16].
Previous work in our group has demonstrated the
prognostic value of the hallmark of EMT, an
E-cadherin to N-cadherin switch (EN-switch), in
localised human prostate cancer [9]. The cadherin
switch has been described in other cancer types, such
as malignant melanoma [17], breast cancer [18],
extrahepatic cholangiocarcinoma [19] and ovarian
high-grade serous carcinoma [20], but the relevance
of the intermediate stages within the spectrum of
epithelial–mesenchymal plasticity has not been much
studied in clinical materials of prostate cancer.
Up-regulation of FOXC2 has been associated with
progression and poor prognosis in various malignancies
such as lung [21,22], colon [23], gastric [24], oral
tongue squamous cell carcinoma [25] and hepatocellular
carcinomas [26]. However, there are still no available
survival data on FOXC2 in prostate cancer.
The aims of this study were to examine the expres-
sion of EMT-related FOXC2, E-cadherin and
N-cadherin in various prostatic tissues and to validate
the results from our previous study on the E-cadherin
to N-cadherin switch [9]. We used a larger series with
extended long-term follow-up and evaluated the
clinico-pathological correlates and relationship to
patient survival. Here we provide a rationale for apply-
ing FOXC2 as a biomarker in prognostication and
novel targeted therapy in prostate cancer and lend sup-
port to the significance of epithelial–mesenchymal
phenotypes in localised and advanced disease.
Materials and methods
Patients and tissues
Series 1 is a retrospective, consecutive series of
338 patients (median age 61.0 years) treated by radical
prostatectomy for clinically localised prostate cancer at
Haukeland University Hospital, Bergen, Norway dur-
ing 1986–2007, in part before the PSA screening era
in Norway. This series has long and complete follow-
up, described previously for the first 104 cases [9,27].
A major part of this series is a clinically heterogeneous
group of Gleason score 7 carcinomas (n = 199). Series
2–5 include 41 cases of benign prostatic hyperplasia
(BPH), 33 non-skeletal metastases (28 from lymph
nodes, the others from rectum, orbita, subcutaneous
tissue, testis and bronchial mucosa), 13 skeletal metas-
tases from different patients, and prostate cancer tis-
sues from 33 castration-resistant prostate cancer
(CRPC) patients (median age 77.3 years) harvested
from the prostate by palliative transurethral re-
section during 1990–2005. The tumours in series
1 and 3–5 are predominantly acinar adenocarcinomas,
including one mucinous adenocarcinoma among the
CRPCs and an adenocarcinoma of foamy gland-type
among the non-skeletal metastases. The non-skeletal
metastases also harboured an intermediate cell type
variant of small cell carcinoma (one case). This study
was approved by the Western Regional Committee for
Medical and Health Research Ethics, REC West (REK
2015/2178).
Clinico-pathological variables
The following variables were recorded: age at diagno-
sis, preoperative s-PSA, clinical stage (UICC TNM
classification of malignant tumours, Eighth edition
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[28]), Gleason grade and score, largest tumour diame-
ter, extra-prostatic extension (EPE), seminal vesicle
invasion, involvement of surgical margins, and pelvic
lymph node status at prostatectomy. Because of the
important revisions in the recommendations from the
International Society of Urological Pathology Consen-
sus Conference in 2005 [29], the slides from the radi-
cal prostatectomies were re-examined and Gleason
graded accordingly. In Norway, s-PSA was introduced
in the early 1990s. Hence, clinical stage T2 dominates
in the first part of series 1, whereas clinical stage T1c
dominates in the second part. Furthermore, the patients
in the early group have larger tumours and more
advanced pathological stages compared to the PSA-
detected tumours in the latter group.
Follow-up
For the 338 patients treated by radical prostatectomy,
time from surgery until biochemical recurrence, clini-
cal recurrence, loco-regional recurrence, skeletal
metastases and death (including cancer specific death)
were recorded. Biochemical recurrence was defined
as s-PSA level of ≥0.5 ng/ml in two consecutive
blood samples if the blood sample was taken before
31 December 1994. Due to the introduction of more
sensitive s-PSA measurements, all biochemical recur-
rences from 1 January 1995 were defined as s-PSA
level of ≥0.2 ng/ml in two consecutive blood samples.
Loco-regional recurrence was defined as a tumour
in the prostatic fossa (confirmed by palpation/
histology/cytology or radiology) or an elevation of s-
PSA following s-PSA level <0.1 ng/ml or a >50%
PSA-drop after local radiation therapy. Skeletal
metastases were found on bone scan, X-ray or MRI.
The last date of follow-up was September 2016 and
the median follow-up time was 147.5 months. For
surviving patients, median follow-up time was
151.5 months. Two patients were lost to follow-up,
169 patients experienced biochemical recurrence,
101 had clinical recurrence (41 with skeletal metasta-
sis, 77 loco-regional recurrences) and 38 patients died
of prostate cancer. In nine patients diagnosed before
the PSA era, disease progression was based on physi-
cal examination or imaging results.
Castration resistance (n = 33) was defined as disease
progression during androgen-ablation therapy. A total
of 24% of the patients (8/33) received additional treat-
ment with anti-androgens (bicalutamide) prior to palli-
ative transurethral resection. Most patients had clinical
progression and increasing s-PSA on consecutive
measurements.
Tissue microarrays
Three tissue cores (diameter 0.6–1.0 mm) were
obtained from the area of highest tumour grade in each
case and transferred to a recipient paraffin block. Tis-
sue microarray (TMA) sections were used for all tissue
subgroups apart from the 13 skeletal metastases.
Immunohistochemistry
Staining was performed on sections (5 μm) from
formalin-fixed and paraffin-embedded tissue.
Forkhead box protein C2
Sections were boiled in Tris-EDTA buffer (pH 9.0) for
20 min at 350 W and incubated overnight at 4 C with
the monoclonal mouse antibody FOXC2 (M02), clone
2H3 (Abnova, Taipei, Taiwan) diluted 1:200 and sta-
ined with HRP EnVision mouse (DAKO, Glostrup,
Denmark) for 30 min at room temperature.
E-cadherin and N-cadherin
Staining for E-cadherin and N-cadherin were per-
formed according to previous protocols [9]. For
E-cadherin, slides were boiled for 15 min at 350 W in
citrate buffer (pH 6.0). The monoclonal mouse
E-cadherin antibody M3612 (diluted 1:400; DAKO)
was used for incubation overnight at 4 C. For
N-cadherin, after boiling in Tris-EDTA buffer (pH 9.0)
for 20 min at 350 W, sections were incubated with the
monoclonal mouse antibody M3613 (diluted 1:25;
DAKO) for 1 h at room temperature.
For all antibodies, the peroxidase was localised by
the diaminobenzidine tetrachloride peroxidase reaction
and counterstained with Mayer’s haematoxylin. Nega-
tive controls were obtained using isotypic immuno-
globulin and antibody diluent omitting the primary
antibody. Samples, including multi-organ TMA sec-
tions, with known reactivity were used as positive
controls.
Evaluation of staining in prostate tissues
The examination and scoring of the tissues were per-
formed by one pathologist (AB), partly by two pathol-
ogists (AB, KG), blinded to patient characteristics and
outcome.
A semi-quantitative and subjective grading system
was used to record the staining; a staining index (SI;
values 0–9) was calculated as a product of staining
intensity (values 0–3) and proportion of positive
tumour cells (0% = 0, 1–10% = 1, 11–50% = 2,
>50% = 3) in all three tissue cores. E-cadherin stained
cell membranes in benign epithelium and variably cell
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membranes in malignant epithelium (Figure 1A,B).
N-cadherin stained both cytoplasm and cell membranes.
The cytoplasmic staining was of variable intensity.
Membranous N-cadherin is presented in this study
(Figure 1C,D). FOXC2 stained mostly the tumour cell
cytoplasm (Figure 1E–H), while nuclear staining was
weak and sporadic in all tissue groups. Cytoplasmic
FOXC2 expression is presented in this study.
There are no standardised cut-off values for any of
the candidate biomarkers. Therefore, the frequency
distribution of the markers, including median and
quartile values, were examined, also considering the
number of cases and events in each subgroup. Catego-
ries with similar survival estimates were merged when
appropriate. To avoid cut-off point selection bias, we
aimed to use robust cut-off values, such as the median.
Hence, cytoplasmic FOXC2 and membranous
E-cadherin were dichotomised by median (SI ≥ 6 ver-
sus others). For membranous N-cadherin, there was a
high number (67%) of negative cases (i.e. SI = 0),
consequently the cut-off point was set as negative
(SI = 0) or positive (SI ≥ 1) SI. The EN-switch was
defined as the subgroup with combined weak membra-
nous E-cadherin and positive membranous N-cadherin
expression. Co-expression of E-cadherin and N-cadherin
was defined as the subgroup with combined membra-
nous E-cadherin above median and positive membra-
nous N-cadherin expression.
Observer variation for FOXC2, E-cadherin and
N-cadherin
Inter-observer variability was tested by two patholo-
gists (AB and KG) by independent re-evaluation,
blinded to earlier registration and clinical data on the
first part of series 1 (radical prostatectomies, n = 104),
and series 2–5 (BPH, non-skeletal metastases, skeletal
metastases, and castration resistant carcinomas). The
inter-observer agreement for FOXC2 staining indices
was good or very good for series 1 (κ-value 0.91,
dichotomised by median SI), and series 2–5 (κ-values
0.70–0.87). The inter-observer agreement for E-
cadherin was very good for series 1 (κ-value 0.96, by
median SI), and series 2–5 (κ-values 0.85–0.87). Inter-
observer agreement for N-cadherin was good, very
good or perfect for series 1 (κ-value 0.96, by
negative/positive SI), and series 2–5 (κ-values
0.63–1.0). Intra-observer variability was tested in a
blinded manner by one pathologist (AB) on a ran-
domly selected subset of 85 cases (25%) from series
1 with very good intra-observer agreement for FOXC2
(κ-value 0.92, by median SI) and on 234 radical pros-
tatectomies from the second part of series 1, with good
intra-observer agreement for E-cadherin (κ-value 0.74,
by median SI) and N-cadherin (κ-value 0.89, by
negative/positive SI).
Biomarkers from previous studies
Biomarkers from previous studies [27,30,31], among
them vascular proliferation index (the percentage of Ki67
positive vessels by dual staining for FVIII and Ki67),
proliferating micro-vessel density by FVIII/Ki67 co-
expression, VEGF-A, proliferation of immature tumour
vessels by Nestin/Ki67 co-expression and Ki67 were
included for comparison.
FOXC2 gene expression
To validate our immunohistochemistry findings, an
external gene expression cancer data set, GSE 25136,
was downloaded from Gene Expression Omnibus,
www.ncbi.nlm.nih.gov/geo [32]. Clinical data on these
patients were collected from Oncomine, www.
oncomine.org [33]. The data set included 79 men
treated with radical prostatectomy between 1993 and
1999 at Memorial Sloan Kettering Cancer Center. The
outcome was biochemical recurrence as classified by
three consecutive increases in the serum level of
PSA > 0.1 ng/ml after radical prostatectomy.
Statistics
Associations between categorical and continuous vari-
ables were assessed by Pearson’s chi-square or Fish-
er’s exact test, the Mann–Whitney U or Kruskal–
Wallis tests, when appropriate. Univariate survival
analyses were done by the product-limit method (log-
rank test) and visualised by Kaplan–Meier plots. Mul-
tivariate survival analyses were done using the Cox’
proportional hazards method and the likelihood ratio
test, including variables with p < 0.15 from univariate
analyses. Model assumptions were examined by log–
log plots. Tests for possible interactions were per-
formed. Inter- and intra-observer agreements were
evaluated by κ-statistics. The SPSS statistical package
versions 24.0 and 25.0 (IBM Corp., Armonk, NY,
USA) were used.
Results
Biomarker expression in radical prostatectomies
In 199 Gleason score 7 carcinomas, 120 of 198 (61%)
showed strong expression of FOXC2. E-cadherin
staining was weak in 42 of 198 (21%), N-cadherin
staining was positive in 69 of 198 (35%), and the
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Figure 1. Immunohistochemical staining of (A–F) localised prostatic carcinomas, (G) castration resistant carcinoma and (H) BPH.
(A) Strong membranous E-cadherin; (B) weak E-cadherin staining with strong staining in a benign gland at the lower right corner;
(C) negative membranous N-cadherin staining; (D) positive membranous N-cadherin staining; (E) strong cytoplasmic FOXC2 in carci-
noma, weaker staining in the benign epithelium to the right; (F) weak FOXC2 staining; (G) strong cytoplasmic FOXC2 staining in castra-
tion resistant carcinoma and (H) weak FOXC2 staining in BPH. Original magnification, ×400.
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EN-switch, with combined weak E-cadherin staining
and positive N-cadherin staining, was present in 20 of
198 (10%) of the cases. A similar distribution was
observed in the complete series 1 (n = 338): 62, 23,
33 and 10%, respectively.
Biomarker associations with clinico-pathological
variables
FOXC2 expression was not associated with any
clinico-pathological features in Gleason score 7 carci-
nomas or in series 1 (Table 1 and see supplementary
material, Table S1).
Among Gleason score 7 carcinomas, the presence of
an EN-switch was associated with high pathological
stage, EPE, large tumour diameter (Mann–Whitney,
p = 0.021) and pelvic lymph node infiltration
(Table 1). Weak E-cadherin expression was associated
with high pathological stage, seminal vesicle invasion
and pelvic lymph node infiltration (Table 1).
Both the EN-switch and weak E-cadherin expres-
sion were associated with all adverse clinico-
pathological variables in series 1, as summarised in
supplementary material, Table S1.
Associations between biomarkers
Among Gleason score 7 cases, strong FOXC2 expres-
sion (above median SI) tended to be associated with
the EN-switch (p = 0.065). Moderate to strong FOXC2
above the lower quartile was significantly or border-
line associated with high vascular proliferation index
by FVIII/Ki67 co-expression (Mann–Whitney, p =
0.031, p = 0.024), proliferating micro-vessel density
Table 1. Associations between FOXC2, EN-switch, E-cadherin, N-cadherin, clinico-pathological features and selected biomarkers in 199
patients with clinically localised prostatic adenocarcinoma, Gleason score 7 (radical prostatectomies)
Variables

























Gleason score** 0.277 0.148 0.131 0.664
3+4 54 (42) 74 (58) 118 (92) 10 (8) 105 (82) 23 (18) 82 (64) 46 (36)
4+3 24 (34) 46 (66) 60 (86) 10 (14) 51 (73) 19 (27) 47 (67) 23 (33)
Extra-prostatic
extension
0.678 0.011 0.181 0.741
Absent 42 (41) 61 (59) 98 (95) 5 (5) 85 (82) 18 (18) 66 (64) 37 (36)
Present 36 (38) 59 (62) 80 (84) 15 (16) 71 (75) 24 (25) 63 (66) 32 (34)
Seminal vesicle
invasion
0.811 0.103 0.014 0.731
Absent 66 (40) 100 (60) 152 (92) 14 (8) 136 (82) 30 (18) 109 (66) 57 (34)
Present 12 (38) 20 (62) 26 (81) 6 (19) 20 (62) 12 (38) 20 (63) 12 (37)
Pathological stage†† 0.867 0.011 0.042 0.530
pT2 40 (39) 63 (61) 98 (95) 5 (5) 87 (84) 16 (16) 65 (63) 38 (37)
≥pT3 38 (40) 57 (60) 80 (84) 15 (16) 69 (73) 26 (27) 64 (67) 31 (33)
Lymph node
infiltration‡‡
0.520 0.010 0.044 0.120
Absent§§ 78 (40) 118 (60) 178 (91) 18 (9) 156 (80) 40 (20) 129 (66) 67 (34)
Present 0 (00) 2 (100) 0 (00) 2 (100) 0 (00) 2 (100) 0 (00) 2 (100)
VEGF-A 0.051¶¶ 0.300 1.000 0.292
Low 18 (35) 34 (65) 41 (79) 11 (21) 35 (67) 17 (33) 34 (65) 18 (35)
High 1 (7) 13 (93) 9 (64) 5 (36) 9 (64) 5 (36) 7 (50) 7 (50)
Nestin-Ki67*** 0.248 0.026 0.065 0.233
Low 18 (45) 22 (55) 35 (85) 6 (15) 31 (76) 10 (24) 28 (68) 13 (32)
High 8 (31) 18 (69) 16 (62) 10 (38) 14 (54) 12 (46) 14 (54) 12 (46)
*Cytoplasmic expression, cut-off by median.
†Subgroup with combined weak membranous E-cadherin and positive membranous N-cadherin expression.
‡Membranous expression, cut-off by median.
§Membranous expression, cut-off by negative/positive.
¶Pearson’s chi-square or Fisher’s exact test.
**Gleason score in radical prostatectomy specimens.
††Pathological stage, UICC TNM Classification of malignant tumours, Eighth edition, 2017 [28].
‡‡Pelvic lymph node infiltration at radical prostatectomy.
§§Includes cases without lymphadenectomy.
¶¶Cut-off by lower quartile.
***Proliferating micro-vessel density by dual Nestin/Ki67 staining.
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by FVIII/Ki67 (Mann–Whitney, p = 0.055, p = 0.031)
and increased VEGF-A, in Gleason score 7 cases and
in series 1 (Table 1 and see supplementary material,
Table S1). In both series, strong cytoplasmic FOXC2
expression was associated with the presence of nuclear
expression of FOXC2 (p = 0.025 and p = 0.001,
respectively).
In Gleason score 7 cases, the EN-switch and weak
E-cadherin were associated with increased vascular
proliferation by Nestin-Ki67 (Table 1). In series
1, weak E-cadherin expression and the EN-switch
were associated with maximum Nestin micro-vessel
density (Mann–Whitney, p = 0.042 and p = 0.003),
increased vascular proliferation by Nestin-Ki67 (see
supplementary material, Table S1) and high tumour
cell proliferation by Ki67 (Mann–Whitney p = 0.032
and p = 0.051). Additionally, the EN-switch was asso-
ciated with increased VEGF-A in series 1 (see supple-
mentary material, Table S1).
In both series, strong membranous N-cadherin was
associated with weak E-cadherin. In series 1, positive
N-cadherin was related to increased vascular prolifera-
tion by Nestin-Ki67 (p = 0.057) (see supplementary
material, Table S1).
Univariate survival analyses, Gleason score 7
In univariate survival analyses of Gleason score
7 patients, strong FOXC2 expression was significantly
associated with clinical recurrence (p = 0.047), skeletal
metastasis (p = 0.011) and cancer-specific survival
(p = 0.006) (Figure 2 and Table 2). Weak E-cadherin
expression and the presence of an EN-switch were sig-
nificantly associated with all end-points, except for the
EN-switch versus biochemical recurrence (p = 0.061)
(Figure 2 and Table 2).
Multivariate survival analyses, Gleason score 7
In Cox’ proportional hazards method of Gleason score
7 patients, the three standard prognostic variables
Gleason score (4+3 versus 3+4), pathological stage
(≥pT3 versus pT2) and preoperative s-PSA (dichoto-
mised by upper quartile; >13.3 versus ≤13.3) (see sup-
plementary material, Table S2) were included in the
model in addition to FOXC2 and the EN-switch.
FOXC2 was an independent predictor of time to clini-
cal recurrence (HR 1.8, p = 0.023), skeletal metastasis
(HR 3.7, p = 0.004) and cancer specific death
(HR 4.8, p = 0.001), together with the EN-switch and
Gleason grade groups (GG3 [4+3] versus GG2 [3+4])
(Table 3).
Survival analyses across all Gleason scores
In univariate survival analyses including all
338 patients from series 1, strong FOXC2 expression
was borderline associated with shorter time to clinical
recurrence (p = 0.073), skeletal metastasis (p = 0.081),
and cancer specific death (p = 0.069) (see supplemen-
tary material, Figure S1 and Table S3). The EN-switch
and weak E-cadherin were strongly and significantly
associated with all end-points (see supplementary
material, Figure S1 and Table S3). Positive N-cadherin
expression was associated with shorter time to skeletal
metastases (p = 0.039).
Including all 338 patients from series 1, and vari-
ables from univariate survival analyses (see supple-
mentary material, Tables S3 and S4) in multivariate
Cox’ regression analysis, the EN-switch was an inde-
pendent predictor of time to skeletal metastases
(HR 3.7, p = 0.001) and cancer specific death
(HR 8.4, p < 0.0005), together with FOXC2 (HR 1.9,
p = 0.057 and HR 2.0, p = 0.061), Gleason grade
groups (≥GG3 [4+3] versus ≤GG2 [3+4]) and patho-
logical stage (≥pT3 versus pT2) (see supplementary
material, Table S5).
Survival analyses by FOXC2 mRNA expression in
radical prostatectomies
The 79 patients were divided into two groups with
high (n = 20) and low (n = 59) FOXC2 mRNA expres-
sion (upper quartile as cut-point). Patients harbouring
cancers with high FOXC2 mRNA expression level
showed shorter time to biochemical recurrence
(p = 0.006) (Figure 3), and a similar result was
observed among Gleason score 7 carcinomas (n = 44;
p = 0.003).
Biomarker expression in different prostatic tissues
FOXC2 expression
FOXC2 staining was strongest among CRPC (median
SI, 6; mean, 6.2), skeletal metastases (median SI, 6;
mean, 5.8), localised carcinomas (median SI, 6; mean,
5.0) and non-skeletal metastases (median SI, 6; mean,
4.7). In comparison, it was lowest among BPH
(median SI, 3; mean, 4.3), (p < 0.0005) (Figure 4A).
E-cadherin expression
E-cadherin expression was lowest among CRPCs
(median SI, 6; mean, 5.3) versus skeletal metastases
(median SI, 6; mean, 6.2), localised cancers (median
SI, 6; mean, 5.8) and non-skeletal metastases (median
SI, 6, mean, 5.7), and highest among hyperplasias
(median SI, 6; mean, 7.4) (p < 0.0005).
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N-cadherin expression
N-cadherin expression was most frequent and stron-
gest among CRPCs (median SI, 1; mean, 1.8) and
skeletal metastases (median SI, 2; mean, 1.3) in con-
trast to localised cancers (median SI, 0; mean, 0.7) and
non-skeletal metastases (median SI, 0; mean, 0.5), and
not observed in BPH (p < 0.0005). In localised carci-
nomas, non-skeletal metastases, skeletal metastases
and CRPC, positive N-cadherin expression was
recorded in 33, 28, 77 and 52% of cases, respectively.
Figure 2. Univariate survival analyses (Kaplan–Meier) of Gleason score 7 prostate cancer patients after radical prostatectomy, by (A–C)
cytoplasmic FOXC2 and (D–F) EN-switch, with clinical recurrence, skeletal metastases and cancer specific death as end-points.
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Table 2. Univariate survival analysis (Kaplan–Meier) for 199 patients with Gleason score 7 carcinoma (radical prostatectomies), using













survival (%) P value*
Biochemical recurrence
FOXC2† 0.174
Low 78 39 61.9 51.0 46.0 46.0
High 120 71 54.7 38.2 36.1 31.6
E-cadherin‡ 0.038
High 156 82 59.7 45.0 42.0 42.0
Low 42 28 49.0 36.9 31.6 25.3
N-cadherin‡ 0.739
Low 129 70 58.0 43.1 39.4 35.8
High 69 40 56.3 43.1 40.2 40.2
EN-switch§ 0.061
Absent 178 95 58.9 45.3 41.4 38.9
Present 20 15 42.8 24.4 24.4 24.4
Clinical recurrence
FOXC2† 0.047
Low 78 21 89.4 77.8 70.6 63.7
High 120 46 83.1 64.9 58.6 39.9
E-cadherin‡ 0.016
High 156 47 89.4 74.2 65.7 51.8
Low 42 20 70.5 53.2 53.2 47.9
N-cadherin‡ 0.402
Low 129 40 87.2 72.0 64.7 51.3
High 69 27 82.5 66.0 60.4 52.8
EN-switch§ 0.004
Absent 178 55 87.9 73.1 65.6 52.3




Low 78 16 90.7 82.4 77.6 70.2
High 120 35 84.0 70.9 64.3 64.3
E-cadherin‡ 0.018
High 156 35 90.1 80.0 72.4 68.1
Low 42 16 73.0 58.7 58.7 58.7
N-cadherin‡ 0.272
Low 129 29 88.8 78.0 70.2 70.2
High 69 22 82.5 71.0 67.9 59.6
EN-switch§ <0.0005
Absent 178 40 89.0 79.5 72.8 69.0
Present 20 11 63.5 40.4 40.4 40.4
Skeletal metastasis
FOXC2† 0.011
Low 78 6 98.7 95.3 93.2 88.3
High 120 21 97.5 84.0 79.0 55.9
E-cadherin‡ 0.004
High 156 15 99.3 93.2 90.4 72.5
Low 42 12 92.7 73.0 65.9 65.9
N-cadherin‡ 0.282
Low 129 14 97.6 90.9 89.1 72.2
High 69 13 98.6 85.0 78.5 71.9
EN-switch§ <0.0005
Absent 178 18 98.3 92.2 89.8 74.2
Present 20 9 95.0 63.6 50.9 50.9
Cancer specific survival
FOXC2† 0.006
Low 78 5 100.0 98.1 93.5 93.5
High 120 19 99.2 93.7 83.3 54.4
(Continues)
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EN-switch and cadherin co-expression
The EN-switch was most prevalent in castration resis-
tant carcinomas (n = 6/33, 18.2%) (p = 0.006), skeletal
metastases (n = 2/13, 15.4%) (p = 0.055) and localised
carcinomas (n = 33/335, 9.9%) (p = 0.036), less fre-
quently in non-skeletal metastases (n = 2/31, 6.5%)
(p = 0.182), as compared to hyperplasias (n = 0/41), in
which the EN-switch was not observed (Figure 4B).
Co-expression of E-cadherin and N-cadherin was most
frequently observed in skeletal metastases (62%) and
CRPC (33%) (p < 0.0005) (Figure 4C).
Survival analyses in castration resistant carcinomas
Within the group of castration resistant cancers, no
convincing survival differences were observed for
FOXC2, E-cadherin, N-cadherin or the EN-switch.
However, co-expression of E-cadherin and N-cadherin
was borderline associated with reduced survival in
these tumours (p = 0.094) (Figure 5), with time from
castration resistance to death as the time variable.
Discussion
Cadherin switching is a hallmark of EMT, important
for tumour invasion and dissemination [3]. FOXC2, an
important EMT-regulator [12], has recently been
highlighted by the discovery of a novel small molecule
inhibitor directly targeting this transcription factor
[11]. In our study, we have demonstrated that FOXC2
is strongly expressed in primary, metastatic and castra-
tion resistant prostate cancers, and is a strong predictor
of outcome, of potential importance for prognostica-
tion and targeted therapy.
We previously reported that E- to N-cadherin
switching, an expression of EMT, was a strong and
independent predictor of disease progression in pros-
tate cancer [9], a finding that is currently sustained in
the prolonged follow-up and expansion of our series.
We are aware of the limitations of retrospective studies
and the heterogeneity among cases during the time
period 1986–2007. However, the current series has a
long follow-up with solid end-points. Still, the findings
need to be validated in an independent cohort with
comparable follow-up. Validation in a more recent
cohort of castration-resistant prostate carcinomas
treated with next generation anti-androgen therapy,
such as abiraterone and enzalutamide, would also be
valuable. The sample sizes of series 1–5 are based on
convenience and not powered to detect a pre-specified
difference.
FOXC2 has been introduced as a mediator of mes-
enchymal differentiation in the course of EMT, down-
stream of TGFβ and other EMT-regulators, and
identified as a decisive factor for carcinoma dissemina-
tion in breast cancer models [12]. Increased expression
of FOXC2 has been linked to oestrogen receptor nega-
tive basal-like breast carcinoma [12] and survival in
various cancer types [21–26], but survival data for
FOXC2 has not yet been presented in prostate cancer.
A majority of clinically localised Gleason score 7 can-
cers are placed in the intermediate risk group
(European Association of Urology 2017 [34]), a large
and heterogeneous group of prostate cancers compris-
ing Gleason grade groups 2 and 3. In order to better
stratify intermediate risk patients to active surveillance
or radical treatment, there is a need for biomarkers
applicable to preoperative biopsy material. High
expression of FOXC2 was a strong predictor of clini-
cal recurrence and cancer specific survival among














survival (%) P value*
E-cadherin‡ 0.002
High 156 12 100.0 97.6 94.4 80.8
Low 42 12 97.6 88.7 67.0 53.3
N-cadherin‡ 0.756
Low 129 14 100.0 95.6 89.9 70.6
High 69 10 98.6 95.1 83.8 80.2
EN-switch§ <0.0005
Absent 178 15 100.0 97.0 93.0 78.4
Present 20 9 95.0 83.5 51.6 43.0
*Log-rank test.
†Cytoplasmic expression, cut-off by median.
‡Membranous expression, cut-off by median (E-cadherin) or negative/positive (N-cadherin).
§Subgroup with combined weak membranous E-cadherin and positive membranous N-cadherin expression.
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along with the EN-switch and Gleason grade groups
3 versus 2. Thus, FOXC2 has the potential to serve as
a biomarker of disease course, may impact surveil-
lance and post-operative follow-up regimens, and ulti-
mately direct tailored therapy.
Strong expression of FOXC2, the EN-switch and
co-expression of E-cadherin and N-cadherin were less
frequently observed in non-skeletal metastases as com-
pared to bone metastases. Prostate carcinomas favour
bone marrow as their home for distant colonisation of
tumour cells and form osteoblastic metastases.
Tumour-induced osteogenesis promotes growth of the
metastatic tumour cells in the bone [35] and FOXC2 is
found to induce osteogenesis [1]. Hence, FOXC2
might be secreted by the carcinoma cells to induce an
osteogenic metastatic niche in the bone marrow. This
may even occur prior to the arrival of the disseminated
tumour cells [36,37]. As lymphatic metastases may not
require EMT [38], the differences in FOXC2 and
cadherin expression between skeletal and non-skeletal
metastases might be explained by these aspects.
The EN-switch was not a very prevalent finding
among bone metastases and CRPC in our series, likely a
reflection of the existence of intermediate states during
EMT or mesenchymal-to-epithelial transition (MET) [2].
Studies dealing with the concurrent immunohistochemi-
cal expression of E-cadherin and N-cadherin in tissue
specimens from human prostate cancer metastases seem
Table 3. Multivariate survival analysis (Cox’ proportional hazards
method) for 199 patients with Gleason score 7 carcinoma
(radical prostatectomies), using clinical recurrence, loco-regional
recurrence, skeletal metastasis and cancer specific death as
end-points
Variables No. of patients HR* 95% CI† P value‡
Clinical recurrence
Gleason score§
3+4 127 1.0 1.4–3.8
4+3 70 2.3 0.0010
Pathological stage¶
pT2 102 1.0 1.0–2.9
≥pT3 95 1.7 0.0340
FOXC2**
Low 77 1.0 1.1–3.1
High 120 1.8 0.0230
EN-switch††
Absent 177 1.0 1.0–3.8
Present 20 2.0 0.0520
Loco-regional recurrence
Gleason score§
3+4 128 1.0 1.2–3.8
4+3 70 2.2 0.0060
Pathological stage¶
pT2 103 1.0 1.2–4.1
≥pT3 95 2.2 0.0090
EN-switch††
Absent 178 1.0 1.3–5.0
Present 20 2.5 0.0150
Skeletal metastasis
Gleason score§
3+4 127 1.0 1.9–9.8
4+3 70 4.3 <0.0005
FOXC2**
Low 77 1.0 1.4–9.5
High 120 3.7 0.0040
EN-switch††
Absent 177 1.0 1.7–8.7
Present 20 3.8 0.0030
Cancer specific survival
Gleason score§
3+4 127 1.0 4.2–40.8
4+3 70 13.2 <0.0005
Pathological stage¶
pT2 102 1.0 1.8–21.2
≥pT3 95 6.1 0.0010
FOXC2**
Low 77 1.0 1.7–13.5
High 120 4.8 0.0010
EN-switch††
Absent 177 1.0 2.7–18.7




§Gleason score in radical prostatectomy specimens.
¶Pathological stage, UICC TNM Classification of malignant tumours, Eighth
edition, 2017 [28].
**Cytoplasmic staining, cut-off by median.
††Subgroup with combined weak membranous E-cadherin and positive mem-
branous N-cadherin expression.
Figure 3. Univariate survival analysis (Kaplan–Meier) in 79 pros-
tate cancer patients by FOXC2 gene expression (59 low
expressors, 20 high expressors) with biochemical recurrence as
end-point.
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to be virtually non-existent. The co-expression of
E-cadherin and N-cadherin in a majority of bone metas-
tases thus corroborates previous experimental knowledge
that partial reversion to an epithelial phenotype,
i.e. partial MET, is necessary for colonisation to mac-
rometastases at distant sites [39], possibly complicating
reversal of EMT as a monotherapeutic approach [2].
Co-expression of E-and N-cadherin in a substantial pro-
portion of the CRPCs in our series could be explained
by partial EMT, with tumour cells transitioning between
epithelial and mesenchymal states. It has earlier been
reported that >80% of circulating tumour cells in
patients with metastatic CRPC co-express epithelial and
mesenchymal markers [40]. The phenotypic plasticity
found in the advanced, castration resistant carcinomas
and metastases in our material may be more important
for the aggressiveness of carcinomas than the end states
[40,41]. In support of this, a trend for reduced survival
among our CRPC patients with a hybrid phenotype
could be demonstrated. Furthermore, the frequent
expression of N-cadherin in metastatic and castration
resistant disease may prove more important for therapeu-
tic strategies than striving for a complete reversal of
EMT. In line with this view, targeting N-cadherin
inhibits prostate cancer progression and castration resis-
tance in vivo [42].
Cytoplasmic FOXC2 expression is presented in this
study, comparable with immunohistochemical studies
on FOXC2 in several other tumour types
Figure 4. (A) Mean FOXC2 SI (95% CI) in benign and malig-
nant prostatic tissues, (B) EN-switch (%) in benign and
malignant prostatic tissues, (C) co-expression (%) of E-
cadherin and N-cadherin in benign and malignant prostatic
tissues.
Figure 5. Univariate survival analysis (Kaplan–Meier) of castration
resistant prostatic carcinomas by E-cadherin and N-cadherin co-
expression with time from diagnosis of castration resistance to
death as end-point.
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[12,22,24–26]. Transcription factors may shuttle
between the nucleus and the cytoplasm [43]. The pre-
dominantly cytoplasmic expression of FOXC2 might
indicate phenotypic plasticity with reversal of EMT in
our material, since the balance between nuclear and
cytoplasmic FOXC2 seems to determine whether
FOXC2 acts to promote EMT or MET [43]. Mainte-
nance of FOXC2 in the cytoplasm of normal epithelial
cells has been shown to be regulated through casein
kinase 2-mediated phosphorylation at serine 124 [44].
The newly described small molecule inhibitor of
FOXC2 (MC-1-F2) induces degradation of FOXC2
and averts its nuclear localisation [11]. Another thera-
peutic approach could be regulation of the shuttling of
FOXC2 between the nucleus and the cytoplasm [45],
for instance through targeting casein kinase 2 [44].
Advanced prostate cancer patients receiving andro-
gen deprivation therapy (ADT) eventually develop
androgen resistance, which is a major determinant of
prostate cancer mortality. ADT represents the standard
treatment for advanced prostate cancer, but unfortu-
nately induces EMT and cancer stem cell (CSC) like
cells in prostate cancer [46,47]. The EMT programme
is linked to the acquisition of CSC properties [48],
which can be induced by FOXC2, leading to metasta-
ses as demonstrated in breast cancer cell line studies
[49]. The pivotal role of FOXC2 in prostate cancer
was demonstrated by indirect suppression of FOXC2
in mice injected with a metastatic prostate cancer cell
line, restoring epithelial phenotype, attenuating CSCs
and, of major significance, resensitising prostate carci-
noma cells to anti-androgen and taxane therapy [50].
It has been appreciated that EMT induces resistance
to chemotherapy and immunotherapy [2]. Thus, it is
exciting that a small molecule inhibitor of FOXC2
now has emerged. Administration of this inhibitor
induced MET by reversal of E- to N-cadherin
switching in breast cancer cell lines expressing high
levels of FOXC2, and reduced CSC properties and
metastatic capabilities [11]. On this background, our
findings of highly increased FOXC2 expression in pri-
mary, metastatic and castration resistant prostatic car-
cinomas, with a strong link to poor outcome, make
FOXC2 attractive for targeted therapy.
FOXC2 has also been described as a regulator of
angiogenesis [15]. In our study, FOXC2 was related to
vascular factors, such as increased vascular prolifera-
tion index and VEGF-A expression, supporting this
theory. The EN-switch was also related to vascular
factors, suggesting that angiogenesis and EMT might
be co-regulated.
The major potential of FOXC2 as a therapy target
lies not only in its role as an important downstream
mediator of EMT, but is underscored by the recogni-
tion of its self-inducing capacity through stimulation
of known upstream regulators of EMT, among these
TGFβ, Twist and others [12]. However, EMT provides
obstacles for effective hormonal intervention and che-
motherapy in prostate cancer. Furthermore, a main
challenge for blocking or reversing EMT in malignan-
cies has been the inherent problems with targeting
transcription factors, i.e. protein–protein interactions
[51]. Using the novel small molecule inhibitor of
FOXC2 in prostate cancer overexpressors may possi-
bly relieve these difficulties. Simultaneous targeting of
EMT or its hybrid states, along with hormonal inter-
vention and chemotherapy, may pave the way for
multi-modal treatment of prostate cancer in the future.
In conclusion, unravelling the expression levels of
FOXC2 and the presence of epithelial–mesenchymal
phenotypes in various settings of prostate cancer, and
the relation to long term outcome, may have important
implications for future prognostication, stratification
and targeted therapy of prostate cancer patients.
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